New Analyst Rating price target $0.37 ..., page-20

No worries mate - sorry I don't have any more...working a bit blind here (this is really a bit of a "if there's smoke there's fire" kind of deal)...

This could potentially be a very strong story here...not just because of the obvious smoke signals. In two main ways there is a very strong business case to be made here, that is not usually the case with many of the ASX biotech and smaller start up health stocks that are just gaining revenue traction:

1) They have a world class facility that is heavily underutilized so Capex is minimal - I wouldn't underestimate this in both tiny start up cost, and time it will take to get product to market.

2) They already have a revenue base of $13mill (larger than a number of ASX hopefuls). This is an established business that obviously hit a rough patch so a turnaround story. Again, not to be underestimated...as this will mean the 23 new drugs should create strong operational leverage

All detailed in the last report - and I think it is a fair assessment

If they can bring more drugs into the fold here and get them to market lookout - I am just going to hold this a bit longer and see what transpires...

Good luck guys - please DYOR